Table 3.
Efficacy parameters.
| Scale | Assessment | Risperidone (n=22) | Aripiprazole (n=13) | F1 | F2 | F3 |
|---|---|---|---|---|---|---|
| Positive symptoms | Baseline | 23.00(6.53) | 24.31(6.92) | 54.04* | 0.853 | 0.313 |
| Follow up | 14.36(6.54) | 15.36(6.18) | ||||
| Negative symptoms | Baseline | 15.80(7.65) | 21.37(8.98) | 7.41* | 4.548* | 1.029 |
| Follow up | 14.18(6.44) | 18.38(7.07) | ||||
| General symptoms | Baseline | 33.33(7.27) | 37.25(10.55) | 6.51* | 3.196 | 0.116 |
| Follow up | 28.09(12.23) | 33.00(10.55) | ||||
| Total PANSS | Baseline | 72.40(17.44) | 76.12(33.16) | 22.23* | 3.390# | 0.000 |
| Follow up | 55.27(17.63) | 67.15(20.67) | ||||
| CGI-S | Baseline | 4.67(1.00) | 3.47(1.27) | 43.03* | 0.503 | 0.016 |
| Follow up | 4.50(1.31) | 3.23(1.23) |
*p<0.05, # p<0.1; F1=Occasion Effect; F2=Group Effect; F3=Group x Occasion Effect.